EPA 2026: From Gross-to-Net Complexity to Commercial Execution at Scale
- Stratence Partners
- 3 days ago
- 1 min read
At EPA 2026, Stratence Partners will contribute to the core commercial debates shaping Pharma today through two executive sessions led by Fernando Ventureira, CEO.
The first session focuses on Gross-to-Net as a structural performance system, addressing why transparency alone is not enough and how organizations can embed pricing discipline into daily decisions across Finance, Market Access and Commercial.
The second session addresses AI-driven commercial transformation, cutting through technology hype to focus on where AI genuinely improves decision quality, execution discipline and long-term autonomy.
Across both sessions, the emphasis is clear:commercial performance improves when Strategy, Pricing and Execution operate as one integrated system.
📍 Meet us at Stand 300A – right at the entrance🎤 Two speaking slots confirmed (Pricing / GTN and Digital / AI tracks)